Published by Benjamin Chiou on 13th December 2023
(Sharecast News) - Oncology drugs group Avacta has announced positive results from its lead pre|CISION programme, AVA6000, which it says has the potential to be "truly remarkable".
URL: http://www.digitallook.com/dl/news/story/33968921/...